Amgen stock: buy or sell?
Updated on:
February 21st, 2020
4
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology\u002Fhematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience.
Should I buy Amgen stock?
You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to define your own trading strategy that matches with your character as inversor. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.Currently, Amgen stock doesn't match any of these trading strategies, so our recommendation is not to buy.
| Buy setup | Elegible |
|---|---|
| New all-time high | No |
| New 52 week high | No |
| Price crossing up 200d MA | No |
| 100d MA crossing up 200d MA | No |
Is Amgen stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.
Unfortunately, we couldn't find any rating for AMGN stock for the last month.Amgen stock analysis
Daily outlook
Amgen stayed steady a tiny 0.29% and closed at $222.79.
Amgen shares stayed constant 0.29% to $222.79 on Feb 21st. AMGN is retaking the upward trend marking a new rising bottom heading to break out over $232.99. On February/4 AMGN price bounced up over the SMA of 100 days demonstrating to be a significant support for this stock. On December, AMGN hit new all time highs, pushing higher previous ATH of $242.81 recorded on December. New ATHs are usual entry points for many trading setups as there aren't higher resistences.
Weekly outlook
Amgen shares stayed constant -0.31% this week, ending at $222.79. Late January AMGN plunged a hair-raising -7.05% in just one week. Early February AMGN boosted a super good 5.79% in just one week.
From a weekly outlook, AMGN marked an uptrend of rising tops and rising bottoms. Since its last top by mid December 2019 at $243.26, price slid and bounced up back from $208.53. Breaking down under $208.53 would cancel the current uptrend and it might test lower supports. Note that $243.26 might act as a resistance line. Not so far away is the last all-time high Amgen marked by mid December 2019. Late September 2019, SMA20w and SMA40w crossed up triggering a rise of 14.69%. Since late July 2019 when AMGN stock price broke up the SMA40w line, it gained $51.05 (29.73%).
Amgen stock price history
Amgen IPO was on June 17th, 1983 at $0.00 per share1. Since then, AMGN stock surged a inf%, with an average of inf% per year. If you had invested $1,000 in Amgen stock in 1983, it would worth $inf today.
1: Adjusted price after possible price splits or reverse-splits.
Amgen stock historical price chart
AMGN stock reached all-time highs on December with a price of $243.26.
Amgen stock price target
How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' AMGN stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we have not detected any price forecast for Amgen stock by any trusted analyst.Financials and fundamental analysis
Earnings date and Earnings per Share
After publishing its last earnings report on April, Amgen . As soon as we get its posted EPS from the earnings report, we will update this report.| Quarter | Reporting date | Estimated EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| 2017-Q2 | - | n/a | 2.91 | n/a |
| 2017-Q3 | 2017-10-25 | 3.11 | 3.27 | 5.1% |
| 2017-Q4 | 2018-02-01 | 3.03 | 2.89 | -4.6% |
| 2018-Q1 | 2018-04-24 | 3.23 | 3.47 | 7.4% |
| 2018-Q2 | 2018-07-26 | 3.52 | 3.83 | 8.8% |
| 2018-Q3 | 2018-10-30 | 3.42 | 3.69 | 7.9% |
| 2018-Q4 | 2019-01-29 | 3.26 | 3.42 | 4.9% |
| 2019-Q1 | 2019-04-22 | 3.48 | n/a | n/a |
| 2019-Q2 | - | n/a | n/a | n/a |
| 2019-Q3 | - | n/a | n/a | n/a |
Annual financial results
Compared to 2017, last anual revenues report draw a good increase of 3.93% to $23,747.00 M dollars. When comparing 2018 vs 2017, on the other hand, profit margin (that is, the net income divided by revenues) climbed a 26.69% to 35.35%. To have an up to date view of the financial situation of Amgen, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2019-Q1 that can be compared to 2018 fiscal year results. Annual Amgen TTM sales up to March 2019 were $23,750.00 and income was $8,075.00 M USD. When comparing this TTM figures with the last reported annuality, we can esteem Amgen business evolution since December 2018: Annual sales up to March, compared to lastest yearly report, stayed steady a tight 0.01%. Likewise, profit margin (net income/sales) decreased at 35.35%.| Year | Sales | YoY | Income/(margin) | YoY |
|---|---|---|---|---|
| 2013 | $18,670 M | - | $5,080 M27.2% | - |
| 2014 | $20,063 M | 7.46% | $5,158 M25.7% | 1.54% |
| 2015 | $21,662 M | 7.97% | $6,939 M32.0% | 34.53% |
| 2016 | $22,991 M | 6.14% | $7,722 M33.6% | 11.28% |
| 2017 | $22,849 M | -0.62% | $1,979 M8.7% | -74.37% |
| 2018 | $23,747 M | 3.93% | $8,394 M35.3% | 324.15% |
| TTM | $23,750 M | 0.01% | $8,075 M34.0% | -3.80% |
Quarterly financial results
Amgen reported $5,557.00 M in sales for 2019-Q1, a -10.80% less compared to previous quarter. Reported quarter income marked $1,992.00 million with a profit margin of 35.85%. Profit margin stepped up a 4.90% compared to previous quarter when profit margin was 30.95%. When comparing revenues to same quarter last year, Amgen sales marked a neutral movement and remained stable a 0.05%.| Quarter | Sales1 | QoQ2 | Income1/(margin) | QoQ2 |
|---|---|---|---|---|
| 2017-Q2 | $5,780 M | - | $2,150 M37.2% | - |
| 2017-Q3 | $5,780 M | 0.00% | $2,020 M34.9% | -6.05% |
| 2017-Q4 | $5,802 M | 0.38% | $-4,264 M-73.5% | -311.09% |
| 2018-Q1 | $5,554 M | -4.27% | $2,311 M41.6% | -154.20% |
| 2018-Q2 | $6,059 M | 9.09% | $2,296 M37.9% | -0.65% |
| 2018-Q3 | $5,904 M | -2.56% | $1,859 M31.5% | -19.03% |
| 2018-Q4 | $6,230 M | 5.52% | $1,928 M30.9% | 3.71% |
| 2019-Q1 | $5,557 M | -10.80% | $1,992 M35.8% | 3.32% |
Amgen ownership
When you are planning to buy shares of a company, it's always worth to have a look its ownership structure.Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Amgen, 0.22% of all outstanding shares are owned by its staff.
Bearish positions for AMGN stock account 0.00%, no big difference from last month.
For a better context understanding, the next table shows ownership data compared to other related companies:
| AMGN | |
|---|---|
| Market cap | $131.7 B |
| Total shares | 591.0 M |
| Float shares | 588.5 M |
| - Institutional holdings (%) | 81.6% |
| - Insider holdings (%) | 0.2% |
| Shares in short selling | 0.0% |
Amgen summary
| Friday, February 21st, 2020 | |
|---|---|
| Open | $222.24 |
| Close | $222.79 |
| Day range | $220.99 - $223.80 |
| Previous close | $222.14 |
| Session gain | 0.29% |
| Average true range | $4.44 |
| 50d mov avg | $232.13 |
| 100d mov avg | $221.84 |
| 200d mov avg | $202.02 |
| Daily pattern | lb02a |
| Weekly pattern | lb03a |
Amgen performance
Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We selected as the bechmarking frame for Amgen stock.| Stock | 3m | 6m | 12m |
|---|---|---|---|
| AMGNAmgen | -2.76% | 13.45% | 22.36% |
Amgen competitors
Unfortunately, we could not find any public company that could be defined as Amgen competitor. This doesn't mean Amgen does not have any competitor in the market, it's just we could not detected it.Latest Amgen stock news
- Seeking AlphaMirati's Stock Gaps Higher On Amgen's Data, Opens Up Massive OpportunityJune 6, 2019
- Seeking AlphaAmgen Breaches Hurdle For Decades Of Research To Bring A New Drug To RealityJune 6, 2019
- InvestorPlaceAmgen Earnings: AMGN Stock Dips Slightly Despite Q1 EPS, Sales BeatApril 30, 2019
- Seeking AlphaAmgen Evenity Approval Just Makes It A HoldApril 18, 2019
- InvestorPlace3 Big Stock Charts for Thursday: Citrix Systems, Goldman Sachs Group and AmgenApril 18, 2019